An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?
<p>Abstract</p> <p>Background</p> <p>When a medicine such as rofecoxib (Vioxx) is withdrawn, or a whole class of medicines discredited such as the selective COX-2 inhibitors (COX-2s), follow-up of impacts at consumer level can be difficult and costly. The Australian Lon...
Main Authors: | Parkinson Lynne, Doljagore Xenia, Gibson Richard, Doran Evan, Notley Lisa, Stewart Williams Jenny, Kowal Paul, Byles Julie E |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-11-01
|
Series: | BMC Public Health |
Online Access: | http://www.biomedcentral.com/1471-2458/11/892 |
Similar Items
-
Merck's actions surrounding Vioxx.
by: Michael Heinley
Published: (2006-06-01) -
A case study of Vioxx using STAMP
by: Couturier, Matthieu (Matthieu Jean)
Published: (2010) -
Study of COX-independentchemopreventive activity ofNSAIDs : NSAIDs chemopreventive action
by: Tofiq, Shokhan
Published: (2015) -
Discrediting the Dutch
by: Rosanne Baars, et al.
Published: (2020-12-01) -
Effect of nonsteroidal anti-inflammatory drug Rofecoxib (Vioxx™) on the bone repair
by: Luiz Alberto Milanezi, et al.
Published: (2008-01-01)